TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25054304

Group type: EXPERIMENTAL
Intervention: Passive recovery (PAS)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Active recovery (ACT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cold-water immersion (CWI)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ingestion of a recovery drink (NUTR)
Number of subjects: 11
Study: 22229527

Group type: EXPERIMENTAL
Intervention: Educational intervention (video and brochure)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (teaching session and Q&A)
Number of subjects: 69
Study: 21478817

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 58

Group type: COMPARATOR
Intervention: CNI therapy
Number of subjects: 58
Study: 19252046

Group type: EXPERIMENTAL
Intervention: Escitalopram for 20 weeks with care manager monitoring
Number of subjects: 60

Group type: COMPARATOR
Intervention: Interpersonal psychotherapy for 12 weekly sessions followed by two monthly booster sessions
Number of subjects: 60
Study: 16988200

Group type: EXPERIMENTAL
Intervention: 100-mg 2-hour intravenous infusion
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 200-mg oral administration twice daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 200-mg/d continuous intravenous infusion
Number of subjects: 32
Study: 15163481

Group type: EXPERIMENTAL
Intervention: Trivalent, intranasal, live attenuated influenza virus vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Events on days with any symptom during the entire outcome period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost benefit analysis based on specific case definition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost benefit analysis based on sensitive case definition
Number of subjects: 0
Study: 10912948

Group type: EXPERIMENTAL
Intervention: Gemcitabine (200 mg/m2, with possible escalation to 250 mg/m2), administered as a 360 min infusion on days 1, 8, and 15 of a 28-day cycle.
Number of subjects: 18
Study: 9487432

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (corticosteroid)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cerebellar infarction or atrophy on CT
Number of subjects: 30
Study: 1396894

Group type: EXPERIMENTAL
Intervention: Porcine surfactant (Curosurf) replacement
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no surfactant treatment)
Number of subjects: 100
Study: 2856785

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg once daily
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + Captopril
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 30650326

Group type: EXPERIMENTAL
Intervention: Tafenoquine (300 mg single dose)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Primaquine (15 mg once daily for 14 days)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Tafenoquine
Number of subjects: 640

Group type: COMPARATOR
Intervention: Primaquine
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Tafenoquine vs. Primaquine
Number of subjects: 640
Study: 29879450

Group type: EXPERIMENTAL
Intervention: Graphic warning label
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Text warning label
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Sugar information label
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Health Star Rating (HSR) label
Number of subjects: 994

Group type: COMPARATOR
Intervention: Control group (no label)
Number of subjects: 994
Study: 27574259

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Postoperative autologous transfusion (PAT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Routine drainage (control)
Number of subjects: 150
Study: 24523332

Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (Eprex) administered hypodermically 10,000 units 3 times a week during 6 months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (30 healthy persons)
Number of subjects: 14
Study: 22949632

Group type: EXPERIMENTAL
Intervention: Assistive listening devices (classroom FM systems) used for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control group (children with dyslexia not using FM system)
Number of subjects: 0
Study: 19175372

Group type: EXPERIMENTAL
Intervention: Combined 585/1,064-nm laser
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL)
Number of subjects: 16
Study: 17134797

Group type: EXPERIMENTAL
Intervention: Sensor Glove System
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional sensory re‐education
Number of subjects: 26
Study: 15218410

Group type: EXPERIMENTAL
Intervention: 150 microg IA apraclonidine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 150 microg IA clonidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: IA normal saline
Number of subjects: 80

Group type: COMPARATOR
Intervention: 50 microg IA apraclonidine
Number of subjects: 80
Study: 12375395

Group type: EXPERIMENTAL
Intervention: ACS4-ACS6
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 9821025

Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin (UFH)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Intravenous low molecular weight heparin (LMWH)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Subcutaneous low molecular weight heparin (LMWH)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 387
Study: 8605054

Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (AP; 300 mg monthly)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX; 160 mg trimethoprim and 800 mg sulfamethoxazole every other day)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Dapsone-pyrimethamine (DP; 100 mg weekly dapsone and 25 mg biweekly pyrimethamine)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Aerosolized pentamidine (AP)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Cotrimoxazole (CTX)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Dapsone-pyrimethamine (DP)
Number of subjects: 197
Study: 2529731

Group type: EXPERIMENTAL
Intervention: Sufentanil (0.15 microgram/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.75 microgram/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Meperidine (0.35 mg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Morphine (0.04 mg/kg)
Number of subjects: 100
Study: 813411

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ethacrynic acid
Number of subjects: 32
Study: 29508236

Group type: EXPERIMENTAL
Intervention: Post-discharge myocardial infarction (PDMI)
Number of subjects: 30051

Group type: EXPERIMENTAL
Intervention: Peak CK ratio < 3
Number of subjects: 30051

Group type: COMPARATOR
Intervention: No PDMI
Number of subjects: 30051
Study: 27333986

Group type: EXPERIMENTAL
Intervention: Chronic heart failure management program including telemonitoring, 24-h information hotline, and patient education.
Number of subjects: 465
Study: 24925671

Group type: EXPERIMENTAL
Intervention: Talux foot (K3)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Proprio-Foot (microprocessor ankle)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Solid ankle cushion heel foot
Number of subjects: 10
Study: 23102611

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 7376
Study: 21813328

Group type: EXPERIMENTAL
Intervention: Food supplementation rich in arginine (peanuts, equivalent to 1 g of arginine/day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Food supplementation rich in arginine (peanuts) in HIV+/TB patients
Number of subjects: 180

Group type: COMPARATOR
Intervention: Low arginine content supplementation (wheat crackers)
Number of subjects: 180
Study: 19380449

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg/day) plus Letrozole (2.5 mg/day)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo plus Letrozole (2.5 mg/day)
Number of subjects: 270
Study: 17050503

Group type: EXPERIMENTAL
Intervention: 10 mg lisinopril
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 50 mg losartan
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 10 mg lisinopril plus 50 mg losartan
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study: 14524646

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ARBs
Number of subjects: 0
Study: 16786660

Group type: EXPERIMENTAL
Intervention: deprim
Number of subjects: 32
Study: 9066355

Group type: EXPERIMENTAL
Intervention: HLA‐DRB1*15+ individuals
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: HLA‐DRB1*03+ individuals
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: TCRB gene polymorphisms
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: TCRBV6S3 allele inheritance in DRB1*03+ individuals
Number of subjects: 358

Group type: COMPARATOR
Intervention: TCRBV6S1/TCRBV6S3 elements linkage disequilibria
Number of subjects: 358
Study: 8117641

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1% ophthalmic solution
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 32
Study: 3534629

Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg b.i.d. for 4 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31623878

Group type: EXPERIMENTAL
Intervention: Water-soluble contrast (WSC) challenge
Number of subjects: 283
Study: 29599089

Group type: EXPERIMENTAL
Intervention: Cervical cancer message
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: CDC message
Number of subjects: 762

Group type: COMPARATOR
Intervention: Control message
Number of subjects: 762
Study: 27399197

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg bd
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 25240207

Group type: EXPERIMENTAL
Intervention: Oxytocin (N=24)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (N=24)
Number of subjects: 48
Study: 22275257

Group type: EXPERIMENTAL
Intervention: Genistein (10mg/kg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study: 20964867

Group type: EXPERIMENTAL
Intervention: Monthly oral ibandronate (150 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with daily 1-hydroxycholecalciferol (Alfacalcidol; 1 μg) and calcium supplement
Number of subjects: 40
Study: 17101256

Group type: EXPERIMENTAL
Intervention: iopamidol 340 (Niopam)
Number of subjects: 1985

Group type: COMPARATOR
Intervention: iomeprol 350 (Iomeron)
Number of subjects: 1985
Study: 12584032

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day; n = 20)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta estradiol (50 microg/day; n = 39)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Urinary CTX (C-terminal cross-linking type I collagen)
Number of subjects: 148
Study: 10646147

Group type: EXPERIMENTAL
Intervention: Silicone IOL (AMO SI‐30NB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PMMA IOL (Pharmacia 812A)
Number of subjects: 40
Study: 9301412

Group type: EXPERIMENTAL
Intervention: Ingestion of 14 g inulin added to a low-fat spread
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control period (no inulin)
Number of subjects: 64
Study: 7687716

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3521207

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low-dose streptokinase (SK) combined with low-dose heparin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both treatments (Heparin and Low-dose SK)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Foot volumetry
Number of subjects: 36
Study: 29797503

Group type: EXPERIMENTAL
Intervention: Allulose 10 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Allulose 5 g
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fructose (any dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Allulose (5 g, 10 g, pooled doses)
Number of subjects: 24
Study: 27285349

Group type: EXPERIMENTAL
Intervention: P5: 4×6×5 s sprints
Number of subjects: 16

Group type: COMPARATOR
Intervention: P240: 4×4 min at 80% VIFT
Number of subjects: 16

Group type: COMPARATOR
Intervention: P120: 7×2 min at 85% VIFT
Number of subjects: 16

Group type: COMPARATOR
Intervention: P30: 2×10×30 s at 90% VIFT
Number of subjects: 16

Group type: COMPARATOR
Intervention: P15: 3×9×15 s at 95% VIFT
Number of subjects: 16
Study: 24438561

Group type: EXPERIMENTAL
Intervention: Light Force (40 g)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heavy Force (120 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no force)
Number of subjects: 20
Study: 22394412

Group type: EXPERIMENTAL
Intervention: Diuretic treatment (group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diuretic and vasodilator treatment (group II)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stable COPD (control group)
Number of subjects: 40
Study: 19946793

Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (dry keeping method)
Number of subjects: 0
Study: 18243665

Group type: EXPERIMENTAL
Intervention: Combination therapy of interferon-gamma (rIFN-gamma or nIFN-gamma) and narrowband UVB (NB-UVB)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Narrowband UVB (NB-UVB) monotherapy
Number of subjects: 15
Study: 16155867

Group type: COMPARATOR
Intervention: T(1rho) imaging method
Number of subjects: 19
Study: 12964857

Group type: EXPERIMENTAL
Intervention: HBO2 therapy (5 sessions of breathing 95% oxygen at 2.5 atm abs for 100 min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HBO2 therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 16
Study: 10932430

Group type: EXPERIMENTAL
Intervention: IPD meta-analyses with statistically significant results
Number of subjects: 0

Group type: COMPARATOR
Intervention: IPD meta-analyses with nonsignificant results
Number of subjects: 0
Study: 8871872

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy at a dose of 5 MU subcutaneously three times weekly for 6 months
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy
Number of subjects: 57
Study: 1518433

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous (SC) octreotide infusion
Number of subjects: 25

Group type: COMPARATOR
Intervention: Octreotide injection
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Octreotide treatment
Number of subjects: 25
Study: 6378615

Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg BID, dose increased biweekly)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30950431

Group type: EXPERIMENTAL
Intervention: Anti-HCV antibody testing
Number of subjects: 3679

Group type: EXPERIMENTAL
Intervention: HCV RNA detection
Number of subjects: 3679

Group type: EXPERIMENTAL
Intervention: Adjusted odds of testing positive for anti-HCV antibody
Number of subjects: 3679

Group type: EXPERIMENTAL
Intervention: HCV subtype characterization
Number of subjects: 3679
Study: 30007559

Group type: EXPERIMENTAL
Intervention: HeartWare HVAD System (n = 308)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Control (HeartMate II) (n = 157)
Number of subjects: 465
Study: 26821868

Group type: EXPERIMENTAL
Intervention: MESSAGE Communication Strategies in Dementia training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 24343353

Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 22802322

Group type: EXPERIMENTAL
Intervention: Bortezomib induction (PAD)
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Bortezomib maintenance (PAD)
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Bortezomib induction and maintenance (PAD)
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Bortezomib in high-risk patients
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Bortezomib in patients with deletion 17p13
Number of subjects: 827
Study: 19606675

Group type: EXPERIMENTAL
Intervention: Melatonin administration for 3 months in patients with functional dyspepsia and H. pylori infection (n=30)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Melatonin administration for 3 months in patients with functional dyspepsia without H. pylori infection (n=30)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (healthy subjects, n=20)
Number of subjects: 80
Study: 17617914

Group type: COMPARATOR
Intervention: Current standard of care
Number of subjects: 2015

Group type: EXPERIMENTAL
Intervention: Current standard of care plus nursing support
Number of subjects: 2015

Group type: EXPERIMENTAL
Intervention: Current standard of care plus a paraprofessional home visitor
Number of subjects: 2015
Study: 12895685

Group type: EXPERIMENTAL
Intervention: 50 microl of Salvia lavandulaefolia essential oil
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10770464

Group type: EXPERIMENTAL
Intervention: Placebo-controlled trials (PCTs)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Comparator-controlled trials (CCTs)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Latest placebo-controlled trials (PCTs)
Number of subjects: 296
Study: 8869897

Group type: COMPARATOR
Intervention: UV‐A1 irradiation (60kJ/m2, 340‐400 nm) for three weeks, five days a week
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: UV‐A1 irradiation (progressively decreasing levels) for six weeks, three days a week
Number of subjects: 26

Group type: COMPARATOR
Intervention: Visible light (> 430 nm) for three weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: UV‐A1 irradiation (six weeks, three days a week)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: UV‐A1 irradiation (twice- and once-weekly)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: UV‐A1 irradiation
Number of subjects: 26
Study: 1740065

Group type: EXPERIMENTAL
Intervention: Outpatient bowel preparation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Inpatient bowel preparation
Number of subjects: 100
Study: 6655288

Group type: EXPERIMENTAL
Intervention: Dengue 2 vaccine (0.5 ml, doses of 10(1.8)‐10(5.5) plaque-forming units)
Number of subjects: 38
Study: 31185041

Group type: EXPERIMENTAL
Intervention: 0.12% betamethasone valerate ointment applied twice a day after washing or bathing by parents
Number of subjects: 0
Study: 29066841

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting cardiovascular mortality risk
Number of subjects: 1378
Study: 25569028

Group type: EXPERIMENTAL
Intervention: High-dose barium impaction therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 54
Study: 23855764

Group type: EXPERIMENTAL
Intervention: FIFA 11+ (n = 42)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (CON, n = 39)
Number of subjects: 81
Study: 21791651

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir/zidovudine/lamivudine (PI group)
Number of subjects: 530

Group type: COMPARATOR
Intervention: abacavir/zidovudine/lamivudine (NRTI group)
Number of subjects: 530
Study: 19822100

Group type: EXPERIMENTAL
Intervention: Oral hyposensitization therapy with low doses of nickel
Number of subjects: 67
Study: 16421461

Group type: EXPERIMENTAL
Intervention: Amisulpride (400 mg/day up-titrated from 100 mg/day over 1 week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 20
Study: 16791717

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy follow-up program
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 112
Study: 10549447

Group type: EXPERIMENTAL
Intervention: Progesterone-releasing vaginal ring (PVR)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Copper T 380A IUD (T-Cu)
Number of subjects: 547
Study: 8896646

Group type: EXPERIMENTAL
Intervention: OCP users
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ovulatory women
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 21
Study: 1725028

Group type: EXPERIMENTAL
Intervention: Ramipril (2.5, 5, or 10 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril (5, 10, or 20 mg once daily)
Number of subjects: 0
Study: 6129368

Group type: EXPERIMENTAL
Intervention: Plasma exchange (six 4-litre plasma exchanges over a 2-week period)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control procedure (seemingly identical to plasma exchange)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plasma exchange and Control groups
Number of subjects: 20
Study: 31915029

Group type: EXPERIMENTAL
Intervention: Emergency Protocols Handbook
Number of subjects: 84

Group type: COMPARATOR
Intervention: Current resuscitation guidelines without the handbook
Number of subjects: 84
Study: 31011797

Group type: EXPERIMENTAL
Intervention: PEG3350 + E
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 29320971

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (verbal and printed nutritional instructions once per month for nine months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no nutritional intervention)
Number of subjects: 31
Study: 27266883

Group type: EXPERIMENTAL
Intervention: Kinesio Taping added to physical therapy (exercise and manual therapy)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (physical therapy only)
Number of subjects: 148
Study: 24792382

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) treatment
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 189
Study: 22698852

Group type: EXPERIMENTAL
Intervention: Lower-body strength training program
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nonspecific upper-body strength training program
Number of subjects: 22
Study: 20926996

Group type: EXPERIMENTAL
Intervention: Tasocitinib (15 mg or 30 mg twice daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 17